MOZOBIL®
Indications/
Mozobil (plerixafor injection) is approved by the United
FDA Approval
States Food and Drug Administration (FDA) to be used
with another agent, granulocyte-colony stimulating
factor (G-CSF), to mobilize hematopoietic stem cells
into the peripheral blood for collection and subsequent
autologous transplantation in patients with non-Hodgkin's
lymphoma (NHL) or multiple myeloma (MM).
How it Works
Releases hematopoietic stem cells from the bone marrow
into the bloodstream for collection and auto transplantation.
Administration Injection under the skin about 11 hours prior to each
and Timing
stem cell collection session for up to 4 consecutive days.
Growth factor is given daily in the morning for 4 days
prior to MOZOBIL and on each morning prior to stem cell
collection (apheresis).
Important Safety Information
· Mozobil in combination with G-CSF increases circulating WBCs.
Your WBC counts will be monitored.
· Thrombocytopenia has been observed in patients receiving Mozobil.
Your platelet counts will be monitored.
· Cancer cells may be released and subsequently collected with your
stem cells during apheresis. Potential effects of infusing cancer cells
during your transplant have not been well studied.
· Your spleen may be examined if you experience pain in the left upper
stomach area or left shoulder area as these may be signs of an enlarged
or burst (ruptured) spleen.
· Mozobil may harm the unborn child when administered to a pregnant
woman. Scientific studies have shown that Mozobil caused harm to
unborn animals. The safety of Mozobil in pregnant women has not been
established in clinical trials. Avoid becoming pregnant while receiving
treatment with Mozobil.
· The most common adverse reactions during HSC mobilization and
apheresis: diarrhea, nausea, tiredness, injection site reaction,, headache,
pain in your joints (arthralgia), dizziness, and vomiting.
Benefits of MOZOBIL for Stem Cell Collection
Compared · Higher success rate: More collections, more stem cells
to Collection
collected, more patients transplanted
with G-CSF · Potential for fewer collections: More patients needed
Alone
only 1 day to collect target number of cells
· Successful engraftment: For nearly all patients
with cells collected with MOZOBIL/G-CSF
Overall
Increased cells collected, decreased costs,
Benefits
more predictable collection
· Age older than 60 years; prolonged disease duration
Risk Factors
· Treatment with melphalan; extensive prior therapy
for Poor
· Extended Revlimid treatment with or without low
Stem Cell
blood counts
Mobilization
· Extensive radiation therapy to bone marrow

---

INTERNATIONAL
MYELOMA
FOUNDATION
What is Multiple Myeloma?
· Multiple myeloma is a cancer of bone marrow
plasma cells which attacks and destroys bone.
· In the US there are approximately 100,000
patients and over 20,000 new cases diagnosed
each year. Despite this fact, there is a lack of
public awareness about this disease.
· Multiple myeloma represents 1% of all cancers
and accounts for 2% of cancer deaths.
· Although the causes of multiple myeloma
are uncertain, exposure to pesticides, nuclear
radiation, and petrochemicals are considered
to be important trigger factors.
· Although there is no known cure, multiple
myeloma is treatable and outcomes are
constantly improving.
800.452.CURE (2873)
in the US & Canada
818.487.7455
International Myeloma Foundation
12650 Riverside Drive, Suite 206
North Hollywood CA 91607-3421
www.myeloma.org
"Until there is a cure, there is the IMF."

---